Welcome to our dedicated page for Immunic news (Ticker: IMUX), a resource for investors and traders seeking the latest updates and insights on Immunic stock.
Immunic, Inc. develops novel oral therapies for neurologic diseases, with a lead program, vidofludimus calcium (IMU-838), focused on multiple sclerosis. Company news commonly covers clinical and scientific presentations, patent protection for vidofludimus calcium, pipeline updates, and corporate communications tied to its late-stage development strategy.
Updates also include governance changes, board and executive appointments, Nasdaq listing compliance, capital actions such as its reverse stock split, and investor conference participation. Immunic's pipeline references additional earlier-stage programs, including IMU-856 and IMU-381, tied to neurodegenerative, chronic inflammatory, and autoimmune-related disease areas.
Immunic (Nasdaq: IMUX) announced on March 31, 2026 the appointment of Jon Congleton to its Board of Directors, effective March 27, 2026.
Mr. Congleton brings nearly 40 years of biopharmaceutical experience, including leadership in CNS commercialization and a role in the U.S. launch of Copaxone. He currently serves as CEO of Mineralys and will support advancement of vidofludimus calcium toward pivotal trial readouts later in 2026 and the company’s transition to a commercial-stage firm.
Immunic (Nasdaq: IMUX) announced that the European Patent Office granted patent EP3713554 covering label-relevant dosing regimens for vidofludimus calcium, protecting all forms (salts, solvates, free acid) in Europe into 2038. The patent may be eligible for an SPC to extend exclusivity potentially into 2043. The USPTO previously granted related protection in 2023; existing U.S. patents provide protection into 2041, and pending filings could extend certain rights into the mid-2040s.
Immunic (Nasdaq: IMUX) will attend investor conferences in March 2026, presenting leadership panels and offering one-on-one investor meetings.
Executives Daniel Vitt, Ph.D., Jason Tardio and Jessica Breu will appear at the Leerink Partners Global Healthcare Conference (March 8–11) and the Stifel 2026 Virtual CNS Forum (March 17–18). Webcasts will be available on the company's Events and Presentations page.
Immunic (Nasdaq: IMUX) reported year-end 2025 results and a corporate update. Key developments include a completed oversubscribed private placement providing $200 million upfront (up to $400 million total), top-line Phase 3 ENSURE RMS data expected by year-end 2026, and plans for an NDA submission in mid-2027 with a targeted approval in 2028.
The company disclosed a net loss of $97.2 million for 2025, R&D expense of $82.0 million, and cash & equivalents of $15.5 million as of Dec 31, 2025. Combined with ~$187.0 million net proceeds from the February 2026 financing, management expects funding into late 2027. Immunic plans a Phase 3 PPMS program and commercial buildout pending trial outcomes.
Immunic (Nasdaq: IMUX) closed an oversubscribed private placement on Feb 17, 2026, raising upfront gross proceeds of $200 million via issuance of 229,076,000 pre-funded warrants at $0.873 each, with warrants to purchase up to an additional $200 million.
Proceeds are intended to fund completion of the Phase 3 ENSURE trials in relapsing multiple sclerosis, initiate a Phase 3 trial in primary progressive multiple sclerosis, and support the company's transition toward a commercial organization, with cash runway expected into late 2027.
Immunic (Nasdaq: IMUX) priced a private placement for up to USD 400 million, with USD 200 million upfront to fund late‑stage programs and commercial transition. Proceeds target completion of Phase 3 ENSURE (top‑line by end‑2026), NDA submission mid‑2027, potential approval in 2028, and initiation of a Phase 3 PPMS program later in 2026. Leadership changes include Simona Skerjanec as interim chair and a CEO search for a commercial leader. The offering includes 229,076,000 pre‑funded warrants and up to 229,076,000 common warrants, expected to close about Feb 17, 2026.
Immunic (Nasdaq: IMUX) will present additional Phase 2 CALLIPER data for vidofludimus calcium at ACTRIMS Forum 2026 (Feb 5-7, San Diego). Poster data report statistically significant MRI improvements versus placebo (reduced Gd+ lesions, lower new/enlarging T2 lesion rates, T2 volume reductions, fewer SELs) and a significant decline in EBV-specific T-cell receptor matches (p=0.0004) in an 87-patient subset, suggesting antiviral activity and effects on both acute and chronic CNS inflammation.
Immunic (Nasdaq: IMUX) reported 2025 progress and near-term milestones for lead asset vidofludimus calcium and pipeline candidate IMU-856. Key achievements: completed enrollment in twin Phase 3 ENSURE trials (1,121 patients in ENSURE-1; 1,100 in ENSURE-2) with synchronized top-line data expected by end of 2026. Positive Phase 2 CALLIPER signals in progressive MS showed reductions in 24-week confirmed disability worsening and >2x probability of 24-week confirmed disability improvement. Long-term OLE EMPhASIS data showed 92.3% free of 12wCDW and 92.7% free of 24wCDW at week 144. USPTO notice allows patent protection into 2041. Company raised capital via $5.1M direct and $65M public offerings.
Immunic (Nasdaq: IMUX) announced that CEO Daniel Vitt, Ph.D. will participate in a fireside chat at the 8th Annual Evercore ISI Healthcare Conference on Thursday, December 4, 2025 at 9:35 am ET in Coral Gables, FL.
A webcast will be available in the Events and Presentations section of Immunic's investor website at https://ir.imux.com/events-and-presentations. Dr. Vitt and President/COO Jason Tardio will also hold one-on-one investor meetings during the conference; meeting requests can be made through Evercore ISI representatives or by contacting Jessica Breu at jessica.breu@imux.com.
Immunic (Nasdaq: IMUX) reported Q3 2025 results and clinical updates on November 13, 2025. Key clinical highlights include statistically significant 24-week confirmed disability improvement (24wCDI) from the phase 2 CALLIPER trial in progressive MS and supportive long-term EMPhASIS OLE data showing ~952 cumulative treatment years and an annualized discontinuation rate of ~6.4% up to 5.5 years.
The company received a U.S. patent allowance covering vidofludimus calcium dose strengths, expected to provide protection into 2041. Twin phase 3 ENSURE trials top-line data in relapsing MS are expected by year-end 2026.
Financials: Q3 net loss was ~$25.6M (Q3) and ~$77.9M (nine months); cash and equivalents were $35.1M with insufficient liquidity to fund operations for 12 months without additional capital.